QIAGEN launches qBiomarker Somatic Mutation PCR Array System
The assays consist of collections of pathway or cancer-specific assays in 96- or 384-well plate formats with a number of pathways (EGFR, ErbB2, etc.) and cancer types.
Laboratory experiments have shown that the PCR arrays provide a sensitivity of as low as 1-2 % mutant DNA in a background of wild-type DNA. The pathway-focused approach also enables an in-depth understanding of the mutations that are present in a specific tumor sample in a short time frame. The experiments require approximately two hours from sample to result and are easy to perform: the DNA is extracted from the sample, amplified if needed, and then used for the PCR array with any block-based real-time cycler.
The mutations covered in the arrays have been selected from comprehensive databases and literature reviews based on their biological relevance and frequency of occurrence.
The utility of somatic mutation status information in identifying key signaling disruptions has been demonstrated in numerous studies. For targeted therapy research, studying the most common and relevant mutations in the context of biological pathways also provides more coverage and thus the most potential for the discovery and verification of clinical biomarkers.
Find out more about the qBiomarker Somatic Mutation PCR Arrays at www.sabiosciences.com/somaticmutation.php.